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OBJECTIVES We sought to evaluate the mechanisms by which nonsurgical septal reduction therapy
(NSRT) reduces left ventricular outflow tract (LVOT) obstruction in patients with hyper-
trophic obstructive cardiomyopathy (HOCM) both acutely and on a long-term basis.
BACKGROUND NSRT reduces LVOT obstruction in patients with HOCM and leads to symptomatic
improvement. The mechanisms involved, however, are not well studied.
METHODS An initial group of 30 HOCM patients (age 46 6 17, 16 women) who underwent NSRT had
echocardiographic studies performed at baseline and six months after the procedure.
Measurements included LVOT diameter, end-diastolic distance between the anterior mitral
leaflet and interventricular septum, septal base function and the angle between LV systolic
flow and the protruding mitral leaflets. In addition, pulse Doppler recordings at a point
2.5 cm apical to the mitral valve were acquired and analyzed for peak and mean ejection
velocity, peak acceleration rate and the ratio of acceleration time to ejection time (AT/ET).
RESULTS Significant changes were observed after the procedure, with widening in the LVOT, thinning
and akinesis of the septal base, decrease in the angle between LV systolic flow and the
protruding mitral leaflets, a decrease in peak acceleration rate and an increase in AT/ET. All
of these variables had significant relations with the decrease in LVOT obstruction (r 5 0.5
to 0.79, p , 0.01). These correlations were then evaluated in a test group of 15 patients who
underwent echocardiographic examinations at baseline, acutely in the catheterization labo-
ratory with ethanol injection and at six weeks post NSRT. Acute changes in peak acceleration
rate (r 5 0.65) and AT/ET (r 5 0.73) related significantly (p , 0.01) to the decrease in
LVOT obstruction with ethanol. At six weeks, changes similar to those noted in the initial
group were observed in LVOT geometry, the angle between LV systolic flow and the
protruding mitral leaflets, peak acceleration rate and AT/ET. In both populations combined,
these parameters accounted for 72% to 77% of the variance in gradient reduction.
CONCLUSIONS Changes in LV ejection dynamics and septal base function account in part for the acute relief
of LVOT gradient after NSRT. The long-term relief of obstruction is dependent on
remodeling of LVOT as well as the changes in LV ejection. (J Am Coll Cardiol 2001;37:
208–14) © 2001 by the American College of Cardiology
Hypertrophic obstructive cardiomyopathy (HOCM) is a
complex disease with a great diversity of presentation. The
clinical course varies markedly, from asymptomatic to heart
failure and sudden death. Molecular studies of the genetic
alterations in this disease have provided some insight into
the heterogeneity of its clinical features (1). Beta-blockers,
the calcium channel blocker verapamil and disopyramide
have traditionally been administered to symptomatic pa-
tients. In some, medical therapy ultimately proves insuffi-
cient to control symptoms and other therapeutic strategies
are needed. In the few patients in whom medical therapy
fails, septal myectomy is usually offered. At experienced
centers, surgery produces a dramatic elimination of the
outflow tract gradient in $90% of the patients along with
reduction of symptoms and improvement in exercise toler-
ance (2–8). Its mechanism appears to be predominantly
through enlarging the left ventricular outflow tract
(LVOT), which in turn decreases the forces causing ob-
struction, usually with a sustained effect (9,10). Recently,
the injection of alcohol into the first major septal coronary
artery has been advanced as a means of reducing septal
thickness and LVOT gradient in HOCM patients (11–14).
Similar mechanisms may be operable after nonsurgical
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septal reduction therapy (NSRT). We hypothesized that
NSRT leads to acute changes in septal base function, and
later on, LV remodeling (including LVOT), which may
result in reducing the obstruction in HOCM patients. The
purpose of this study, therefore, was to examine these
mechanisms both acutely and on a longer term basis.
METHODS
The initial patient population consisted of 30 consecutive
subjects (age 46 6 17 years, 16 women) with severe,
symptomatic HOCM despite maximal medical therapy who
underwent NSRT at our institution. All patients were in
sinus rhythm and had asymmetric septal hypertrophy and a
baseline LVOT gradient $40 mm Hg at rest. Twenty-nine
patients were receiving beta-blockers, 12 were on verapamil,
and 10 were on disopyramide. On follow-up only 10 were
still receiving beta-blockers (at a lower dose compared with
baseline). Baylor College of Medicine’s Institutional Review
Board approved the study protocol, and all patients provided
written, informed consent prior to participation. The echo-
cardiographic evaluations were performed at baseline and six
months after NSRT.
Echocardiographic studies. Echocardiograms were per-
formed on either an Acuson or a Hewlett-Packard ultra-
sound imaging system. Patients were imaged while in a left
lateral position in the echocardiography laboratory and
while in a supine position in the catheterization laboratory.
Standard parasternal and apical views were acquired first.
Color Doppler was applied in these views to assess the
severity of mitral regurgitation (MR) and to help determine
the location of intraventricular gradients. Color-guided
continuous-wave Doppler was performed in the apical views
to determine the peak LVOT gradient, with care taken to
avoid contamination with the MR jet. In the apical long-
axis view, the sample volume was positioned at a point
2.5 cm apical to the mitral coaptation locale and 1 cm from
the interventricular septum. This site was chosen in order to
record LV systolic flow far from the area of septal leaflet
contact and therefore avoid recording of the flow accelera-
tion developing in relation to LVOT obstruction (15).
Echocardiographic analysis. Investigators blinded to the
patient’s identity and clinical status performed the analysis.
In the parasternal long-axis views, septal base thickness and
excursion, systolic LVOT diameter and the end-diastolic
distance between the anterior mitral valve leaflet (AML)
and the septum were measured. The mean interobserver
differences for LVOT diameter and AML septal distance
measurements were 0.2 6 0.1 and 0.15 6 0.1 cm, respec-
tively. In the short-axis views, septal base function was
assessed as: (end-systolic thickness 2 end-diastolic
thickness)/end-diastolic thickness (mean interobserver dif-
ference 5 5% 6 3%; mean intraobserver difference 5 3% 6
2%). Mitral regurgitation was assessed utilizing the size of
the regurgitant jet in relation to the left atrial (LA) area
(16). A semiquantitative score was applied where 0 5 no or
trivial MR, 1 5 mild MR, 2 5 moderate MR and 3 5
severe MR (intra- and interobserver 100% agreement). The
direction of the color-flow stream was determined in the
parasternal long-axis view as the angle between the line
bisecting color flow and LV basal posterior wall (10). In the
apical five-chamber view, LV flow direction was determined
by a line bisecting systolic flow as noted by color Doppler,
and the angle of this line with the protruding mitral leaflets
was then measured (mean interobserver difference 5 6 6 3
degrees; mean intraobserver difference 5 3 6 2 degrees)
(17). The Doppler tracings at the point 2.5 cm apical to the
mitral coaptation locale were analyzed for peak and mean
velocity, peak acceleration rate, acceleration time and ejec-
tion time. The ratio between the acceleration and ejection
times (AT/ET) was also determined. Peak LVOT gradient
was calculated as: gradient (mm Hg) 5 4v2 m/s) (18). Left
ventricular volumes and ejection fraction were calculated as
recommended by the American Society of Echocardiogra-
phy (19).
Test population. The relations identified in the initial
group of patients were validated in 15 consecutive patients
(age 46 6 15 years, six women). All 15 patients were on
beta-blockers and/or verapamil at baseline. Cardiac medi-
cations were stopped for three days before NSRT. At six
weeks, only five patients with some recurrence in LVOT
gradient were still on beta-blockers, though at a lower dose.
Data were acquired at baseline, immediately after NSRT in
the catheterization laboratory and six weeks afterward.
Statistical analysis. Paired t tests were used to evaluate the
changes after NSRT in the initial population. Repeated
measures of ANOVA with Bonferroni correction were
applied to compare the Doppler and LV geometric changes
at the three different time intervals of data acquisition in the
test population. Regression analysis was utilized to relate the
changes in LVOT gradient to the two-dimensional and
Doppler measurements. Significance was set at a p value
#0.05.
RESULTS
Initial population. All but one of the 30 patients experi-
enced a significant reduction in LVOT gradient. Septal
reduction therapy was not possible in the patient with an
unchanged gradient because of unsuitable coronary anat-
omy. Six months after NSRT, septal basal thickness was
Abbreviations and Acronyms
AML 5 anterior mitral leaflet
AT 5 acceleration time
ET 5 ejection time
HOCM 5 hypertrophic obstructive cardiomyopathy
LA 5 left atrial
LVOT 5 left ventricular outflow tract
MR 5 mitral regurgitation
NSRT 5 nonsurgical septal reduction therapy
SAM 5 systolic anterior motion
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significantly less (p , 0.01), as was its systolic function,
with this myocardial segment developing features of scar
tissue (i.e., thinning and akinesis) but with no paradoxical
septal motion noted in this cohort. The systolic excursion
of the septum towards the mitral valve decreased from a
median of 0.6 cm at baseline to 0 cm (range 5 0 to
0.2 cm) at six months. Several changes were also observed
in the LVOT. The LVOT widened as the basal inter-
ventricular septum became thinner (Fig. 1), which led to
an increase in the end-diastolic distance between the
AML and the basal septum (Table 1). Importantly,
several significant relations were present between LVOT
gradient reduction and these geometric changes (Fig. 2).
Regarding mitral leaflet motion, systolic anterior motion
(SAM) of the mitral valve was present, with mitral-septal
contact extending for $30% of systole’s duration at
baseline. After NSRT, the systolic distance between the
mitral valve and septum was .1 cm in 23 patients and
,1 cm in six patients, with none having mitral-septal
contact.
Accompanying the remodeling of the LVOT, the angle
between the direction of ventricular systolic blood flow and
LV posterior wall (58 6 11 to 30 6 10 degrees, p , 0.01),
as well as between the flow direction and the coapted mitral
leaflets, decreased (Table 1, p , 0.01) and accounted for
41% of the variance observed in gradient reduction (Fig. 3).
Of note, changes in LV ejection also appeared to play a role
in gradient reduction. After NSRT, the peak acceleration
rate at the point proximal to LVOT obstruction was
significantly less and there was an increase in the AT/ET
ratio. Both of these parameters also related significantly to
the gradient reduction at six months (Fig. 4).
Figure 1. Parasternal long-axis view (LAX) of left ventricular outflow tract at baseline and six months after nonsurgical septal reduction therapy (NSRT).
Note the thinning of the septal base and the widening of the outflow tract.
Figure 2. Relation of the change in left ventricular outflow tract gradient to that in left ventricular outflow tract (LVOT) diameter (left) and end-diastolic
mitral septal distance (right) as observed in the initial population. AML 5 anterior mitral leaflet.
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Test population (Table 2). In the catheterization labora-
tory, immediately after intracoronary ethanol injection, peak
LVOT gradient was significantly lower. Changes were
observed in peak acceleration rate and AT/ET (Fig. 5), as
well as in septal base function. These parameters were
significantly related to the reduction in LVOT gradient
(Fig. 6). Systolic septal excursion toward the mitral valve
was reduced from 0.5 6 0.3 cm at baseline to 0.3 6 0.15 cm
in the catheterization lab (p , 0.05). Although SAM was
still observed in the acute studies, the duration of the
mitral-septal contact was ,30% of systole. No changes were
noted in the LVOT diameter or in the angle between AML
and blood flow. MR improvement paralleled the improve-
ment in LVOT obstruction (r 5 0.81, p , 0.01).
After six weeks, LVOT diameter and the distance between
AML and the septum were significantly higher in comparison
to baseline (Fig. 7). Both the angle between AML and blood
flow as well as basal septal thickness and septal systolic
excursion (0.2 cm, p , 0.05 vs. baseline) were significantly
lower. In nine patients the systolic distance between the mitral
leaflet and the septum was .1 cm, but in six cases, mitral-
septal contact was still present (in four patients ,30% and in
two patients $30% of systole). In general, the acute changes in
LV ejection dynamics (peak acceleration rate and AT/ET)
were preserved at six weeks (Table 2).
Interestingly, five patients had some recurrence of LVOT
gradient elevation at six weeks despite an initial acute
reduction of $50%. This elevation occurred despite a
decrease in septal basal thickness and in septal systolic
function. Also, all five patients demonstrated no change in
the angle between AML and blood flow or the angle
between blood flow and LV posterior wall, and their peak
acceleration rate and AT/ET approached baseline values.
Furthermore, LVOT diameter in these five patients had a
minimal increase (1.82 6 0.08 vs. 1.88 6 0.13, p 5 0.07).
These five patients had a mean volume of 1.3 6 1 ml of
ethanol injection versus 2.8 6 1 ml in the other 10 (p 5
0.08). Both the mean value of the peak CK (750 6 300 vs.
1,560 6 550, p 5 0.07) and the septal area opacified during
intracoronary contrast injection (3.3 6 1.9 vs. 6.5 6
1.5 cm2, p 5 0.06) were lower.
At the end of the study, the initial and test populations were
combined in order to examine the impact of changes in LVOT
geometry, the angle between AML and blood flow, and
ventricular ejection on the long-term reduction in LVOT
gradient. Significant results that were similar in each separate
group of patients were observed in the total population.
Multiple regression models (Table 3) demonstrated that, in
general, changes in LVOT geometry, the angle between AML
Figure 3. Relation of the change in left ventricular outflow tract (LVOT)
gradient to that in the angle between left ventricular systolic flow and mitral
leaflets as observed in the initial population. AML 5 anterior mitral leaflet.
Table 1. LV Changes After NSRT in the Initial Population
Baseline Six Months
LVOT gradient (mm Hg) 66 6 22 12 6 20*
Heart rate 67 6 14 66 6 10
LVOT diameter (cm) 1.6 6 0.2 2.1 6 0.2*
Distance between AML
and septum (cm)
0.8 6 0.5 1.3 6 0.5*
Septal base thickness (cm) 2.3 6 0.4 1.5 6 0.5*
Septal base thickening (%) 23 6 7 0 6 8*
Angle between mitral valve
and LV systolic flow
60 6 13 38 6 18*
Peak ejection velocity (cm/s) 113 6 36 96 6 34
Mean ejection velocity (cm/s) 73 6 21 67 6 20
Peak acceleration rate (cm/s2) 1,590 6 686 1,064 6 469*
AT/ET 0.4 6 0.17 0.52 6 0.16†
LV end-diastolic volume (mls) 110 6 15 132 6 12†
LV ejection fraction (%) 72 6 8 68 6 8†
LV stroke volume (mls) 79 6 14 90 6 11†
MR severity 1.5 6 0.5 0.5 6 0.5*
*p , 0.001, †p 5 0.05.
AT/ET 5 acceleration time/ejection time; AML 5 anterior mitral leaflet; LV 5
left ventricular; OT 5 left ventricular outflow tract; MR 5 mitral regurgitation.
Table 2. LV Changes After NSRT in the Test Population
Baseline
Acutely
After
Ethanol Six Weeks
LVOT gradient (mm Hg) 98 6 27 22 6 15* 35 6 33*
Heart rate (bpm) 78 6 12 84 6 12 80 6 14
LVOT diameter (cm) 1.6 6 0.15 1.6 6 0.2 2.1 6 0.3*‡
Distance between AML
and septum (cm)
0.7 6 0.5 0.8 6 0.5 1.2 6 0.7*‡
Septal base thickness (cm) 2.2 6 0.6 2.2 6 0.4 1.7 6 0.5*‡
Septal base thickening (%) 22 6 8 12 6 7* 12 6 10*
Angle between mitral valve
and LV systolic flow
57 6 8 53 6 10 40 6 12†§
Peak ejection velocity (cm/s) 106 6 35 91 6 33 98 6 30
Mean ejection velocity (cm/s) 70 6 17 60 6 19 66 6 10
Peak acceleration rate
(cm/s2)
1611 6 493 975 6 390* 1123 6 416*
AT/ET 0.3 6 0.1 0.46 6 0.1† 0.43 6 0.16†
LV end-diastolic volume
(mls)
112 6 20 135 6 15†
LV ejection fraction (%) 70 6 7 66 6 7
LV stroke volume (mls) 78 6 15 89 6 12†
MR severity 1.5 6 0.8 0.7 6 0.7* 0.5 6 0.6*
*p , 0.001 vs. baseline, †p 5 0.05 vs. baseline, ‡p , 0.001 vs. acute study (post
ethanol), §p 5 0.05 vs. acute study (post ethanol).
Abbreviations as in Table 1.
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and blood flow, septal function and LV ejection dynamics
accounted for 72% to 77% of the variance in the magnitude of
gradient reduction. Likewise, in the 45 patients combined, MR
severity decreased in parallel to the improvement in LVOT
obstruction (r 5 0.83, p , 0.01).
DISCUSSION
The present study demonstrates that changes in LV ejection
dynamics and septal base function account in part for the
acute relief of LVOT gradient after NSRT. The long-term
relief of LVOT obstruction, however, appears to be depen-
dent on remodeling of LVOT together with changes in LV
flow and ejection.
Mechanism of the acute relief of LVOT obstruction with
NSRT. As the present study shows, NSRT induces an acute
decrease in septal thickening and peak acceleration rate of LV
ejection with no geometric changes. These observations indi-
cate that changes in ejection and septal thickening alone play
an important role in relieving obstruction. Furthermore, be-
cause the change in septal excursion is small (0.2 cm), the
decrease in flow acceleration appears to be the more important
factor in reducing obstruction acutely.
LVOT obstruction is related to the apposition of mitral
valve leaflets with the interventricular septum (20), which
occurs as both the basal septum and mitral leaflet(s) move
toward one another. Because the acute interruption of basal
septum blood flow results in its hypo- or akinesis, it is not
surprising that the relief of outflow tract obstruction was in part
related to the extent of septal dysfunction. Interestingly, mitral
valve motion was apparently not restricted, as the mitral valve
had the same excursion in diastole and continued to move
toward the septum during systole. These findings indicate that
NSRT has no immediate effect on the mitral valve apparatus.
In addition, there appear to be global changes in LV ejection
that take place acutely. The peak acceleration rate at a point
proximal to LVOT obstruction was significantly lower. This
alteration led to later onset of the dynamic narrowing of the
LVOT. Accordingly, less time was available for the progressive
increase in outflow gradient (15). The electromechanical
changes after NSRT with the development of bundle branch
Figure 4. Relation of the change in left ventricular outflow tract gradient (LVOT) to that in peak acceleration rate (left) and acceleration time/ejection time
(AT/ET) (right) in the initial population.
Figure 5. Pulse Doppler recordings of left ventricular systolic flow at a point 2.5 cm apical to the mitral valve. The left panel shows the baseline data with
immediate changes after ethanol injection in the middle panel and the six-week results on the right. Notice the increase in acceleration time relative to
ejection time. NSRT 5 nonsurgical septal reduction therapy.
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block (right bundle branch block alone in 60% and with left
anterior hemiblock in 20%) and further inhomogeneity in LV
contraction (21) may be reasons for the lower acceleration rate
and the later onset of the peak ejection velocity. Interestingly,
pacemaker therapy in HOCM patients—with ensuing inho-
mogeneity in LV contraction—was recently reported to pro-
duce a rightward shift in the end-systolic pressure–volume
relation (22), lending further credence to the hypothesis
relating conduction abnormalities to the reduction in the
acceleration rate. Alternatively, it is also possible that acute
septal ischemia or infarction lead to slower acceleration of LV
ejection as the septal contribution to LV systolic function
diminishes.
Mechanism of the long-term relief of LVOT obstruction
with NSRT. Our study shows the important contribution
of LVOT widening to the relief of obstruction after NSRT.
LVOT widening develops secondary to infarction necrosis
and replacement fibrosis of the septal base. This LVOT
remodeling is already apparent by six weeks and in some
patients further widening develops at later follow-up. Of
note, this mechanism is similar to the acute results induced
by surgical myectomy, which has been shown to be associ-
ated with relief of obstruction and symptomatic improve-
ment (2–10). There are additional reasons for the relief of
LVOT obstruction by NSRT. Mitral valve leaflets have
been observed to be redundant (20,23,24) and anteriorly
displaced (25) in patients with HOCM. Consequently, they
readily protrude into the LVOT stream, making them
amenable to the action of the drag forces. These forces have
direct relations with the LV ejection velocity and the
exposed surface area of the protruding leaflets such that the
drag forces push the mitral leaflets against the septum and
contribute to LVOT obstruction. Following NSRT, the
angle between ventricular flow and mitral valve leaflets
decreases as the leaflets become more parallel with the
direction of blood flow. This happens as flow is directed
anteriorly and septally. The ejection velocity proximal to the
mitral valve also decreases after the procedure. In all
Figure 6. Relation of the change in left ventricular outflow tract (LVOT) gradient acutely in the catheterization laboratory to that in peak acceleration rate
(left) and acceleration time/ejection time (AC/ET) (right) in the test population.
Figure 7. Relation of the change in left ventricular outflow tract gradient to that in left ventricular outflow tract (LVOT) diameter (left) and end-diastolic
mitral septal distance (right) six weeks after NSRT as observed in the test population. AML 5 anterior mitral leaflet.
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likelihood, therefore, the drag forces decrease with success-
ful NSRT. Likewise, similar observations were made after
surgical reduction of the interventricular septum (10). Fur-
thermore, changes in LV ejection dynamics still appear to
play a role in the reduction of outflow tract gradient, but
with a somewhat lower contribution in comparison to the
geometric changes.
The recurrence of some outflow tract obstruction in five of
the 15 test group patients in association with smaller amounts
of ethanol injection and smaller infarcts suggests that not only
a critical site but also a certain threshold extent of septal
infarction is needed for the success of this procedure. However,
this remains a hypothesis for further investigation.
Acknowledgments
We thank the reviewer for the helpful and stimulating
comments. The authors gratefully acknowledge the assis-
tance of Maria E. Frias.
Reprint requests and correspondence: Dr. Sherif F. Nagueh,
Cardiology Section, 6550 Fannin Street, SM-1246, Houston,
Texas 77030. E-mail: sherifn@bcm.tmc.edu.
REFERENCES
1. WHO/ISFC Task Force. Report of the WHO/ISFC Task Force on
the definition and classification of cardiomyopathies. Br Heart J
1980;44:672–3.
2. Morrow AG. Hypertrophic subaortic stenosis: operative methods
utilized to relieve left ventricular outflow obstruction. J Thorac
Cardiovasc Surg 1978;76:423–30.
3. Williams WG, Wigle ED, Rakowski H, Smallhorn J, LeBlanc J,
Trusler GA. Results of surgery for hypertrophic obstructive cardiomy-
opathy. Circulation 1987;76:V104–8.
4. Mohr R, Schaff HV, Danielson GK, Puga FJ, Pluth JR, Tajik AJ. The
outcome of surgical treatment of hypertrophic obstructive cardiomy-
opathy: experience over 15 years. J Thorac Cardiovasc Surg 1990;97:
666–74.
5. Seiler C, Hess OM, Schoenbeck M, et al. Long term follow-up of
medical versus surgical therapy for hypertrophic cardiomyopathy: a
retrospective study. J Am Coll Cardiol 1991;17:634–42.
6. ten-Berg JM, Suttorp MJ, Knaepen PJ, Ernest SM, Vermeulen FE,
Jaarsma W. Hypertrophic obstructive cardiomyopathy: initial results
and long term follow-up after Morrow septal myectomy. Circulation
1994;90:1781–5.
7. Heric B, Lytle BW, Miller DP, Rosenkranz ER, Lever HM, Cosgrove
DM. Surgical management of hypertrophic obstructive cardiomyopathy:
early and late results. J Thorac Cardiovasc Surg 1995;110:195–206.
8. McCully RB, Nishimura RA, Tajik AJ, Schaff HV, Danielson GK.
Extent of clinical improvement after surgical treatment of hypertrophic
obstructive cardiomyopathy. Circulation 1996;94:467–71.
9. Spirito P, Maron BJ, Rosing DR. Morphologic determinants of hemo-
dynamic state after ventricular septal myotomy-myectomy in patients with
obstructive hypertrophic cardiomyopathy. M mode and two-dimensional
echocardiographic assessment. Circulation 1984;70:984–95.
10. Nakatani S, Schwammenthal E, Lever HM, Levine RA, Lytle BW,
Thomas JD. New insights into the reduction of mitral valve systolic
anterior motion after ventricular septal myectomy in hypertrophic
obstructive cardiomyopathy. Am Heart J 1996;131:294–300.
11. Sigwart U. Non-surgical myocardial reduction for hypertrophic ob-
structive cardiomyopathy. Lancet 1995;346:211–4.
12. Knight C, Kurbaan AS, Seggewiss H, et al. Non-surgical septal
reduction for hypertrophic obstructive cardiomyopathy: outcome in
the first series of patients. Circulation 1997;95:2075–81.
13. Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt H,
Strick S. Percutaneous transluminal septal myocardial ablation in
hypertrophic obstructive cardiomyopathy: acute results and 3-month
follow-up in 25 patients. J Am Coll Cardiol 1998;31:252–8.
14. Lakkis NM, Nagueh SF, Kleiman NS, et al. Echocardiography guided
ethanol septal reduction for hypertrophic obstructive cardiomyopathy.
Circulation 1998;98:1750–5.
15. Sherrid MV, Pearle G, Gunsburg DZ. Mechanism of benefit of
negative inotropes in obstructive hypertrophic cardiomyopathy. Cir-
culation 1998;97:41–7.
16. Helmcke F, Nanda NC, Hsiung MC, et al. Color Doppler assessment of
mitral regurgitation with orthogonal planes. Circulation 1987;75:175–83.
17. Sherrid MV, Chu CK, Delia E, Mogtader A, Dwyer EM Jr. An
echocardiographic study of the fluid mechanics of obstruction in
hypertrophic cardiomyopathy. J Am Coll Cardiol 1993;22:816–25.
18. Sasson Z, Yock PG, Hatle LK, Alderman EL, Popp RL. Doppler
echocardiographic determination of the pressure gradient in hypertro-
phic cardiomyopathy. J Am Coll Cardiol 1988;11:752–6.
19. Schiller NB, Shah PM, Crawford M, et al. Recommendations for
quantitation of the left ventricle by two-dimensional echocardiogra-
phy. American Society of Echocardiography Committee on Standards,
Subcommittee on Quantitation of Two-Dimensional Echocardio-
grams. J Am Soc Echocardiogr 1989;2:358–67.
20. Grigg LE, Wigle ED, Williams WG, Daniel LB, Rakowski H.
Transesophageal Doppler echocardiography in obstructive hypertro-
phic cardiomyopathy: clarification of pathophysiology and importance
in intraoperative decision making. J Am Coll Cardiol 1992;20:42–52.
21. Henein MY, O’Sullivan CA, Ramzy IS, Sigwart U, Gibson DG.
Electromechanical left ventricular behavior after nonsurgical septal
reduction in patients with hypertrophic obstructive cardiomyopathy.
J Am Coll Cardiol 1999;34:1117–22.
22. Pak PH, Maughan WL, Baughman KL, Kieval RS, Kass DA.
Mechanism of acute mechanical benefit from VDD pacing in hyper-
trophied heart: similarity of responses in hypertrophic cardiomyopathy
and hypertensive heart disease. Circulation 1998;98:242–8.
23. Moro E, ten Cate FJ, Leonard JJ, Hugenholtz PG, Roelandt J. Gen-
esis of systolic anterior motion of the mitral valve in hypertrophic
cardiomyopathy: an anatomical or dynamic event? Eur Heart J
1987;8:1312–21.
24. Klues HG, Proschan MA, Dollar AL, Spirito P, Roberts WC, Maron
BJ. Echocardiographic assessment of mitral valve size in obstructive
hypertrophic cardiomyopathy. Anatomic variation from mitral valve
specimen. Circulation 1993;88:548–55.
25. Jiang L, Levine RA, King ME, Weyman AE. An integrated mecha-
nism for systolic anterior motion of the mitral valve in hypertrophic
cardiomyopathy based on echocardiographic observations. Am Heart J
1987;113:633–44.
Table 3. Relation of LVOT Gradient Reduction to Changes in
Outflow Geometry and LV Ejection
Variable
Acute Cath
Lab Study
(n 5 15)
(r value)
Chronic Study
(n 5 45)
(r value)
1. LVOT diameter — 0.78*
2. Distance between AML &
septum
— 0.77*
3. Angle between mitral valve and
LV systolic flow
— 0.63*
4. Septal base thickening 0.6* 0.5*
5. Peak acceleration rate 0.65* 0.58*
6. AT/ET 0.73* 0.59*
1 1 2 1 3 1 4 — 0.85*
1 1 2 1 3 1 4 1 5 — 0.86*
1 1 2 1 3 1 4 1 5 1 6 — 0.88*
*p , 0.01.
Abbreviations as in Table 1.
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